PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-57.23%
Revenue decline while TRAW shows 1.79% growth. Joel Greenblatt would examine competitive position erosion.
No Data
No Data available this quarter, please select a different quarter.
-57.23%
Gross profit decline while TRAW shows 1.79% growth. Joel Greenblatt would examine competitive position.
No Data
No Data available this quarter, please select a different quarter.
-15.08%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
-0.47%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.89%
Operating expenses reduction while TRAW shows 13.10% growth. Joel Greenblatt would examine advantage.
-10.89%
Total costs reduction while TRAW shows 13.19% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
3.20%
D&A growth less than half of TRAW's 33.33%. David Dodd would verify if efficiency is sustainable.
5.74%
EBITDA growth while TRAW declines. John Neff would investigate advantages.
-120.42%
Both companies show margin pressure. Martin Whitman would check industry conditions.
5.53%
Operating income growth while TRAW declines. John Neff would investigate advantages.
-120.91%
Both companies show margin pressure. Martin Whitman would check industry conditions.
3.85%
Other expenses growth less than half of TRAW's 167.10%. David Dodd would verify if advantage is sustainable.
5.62%
Pre-tax income growth 50-75% of TRAW's 10.27%. Martin Whitman would scrutinize operations.
-120.69%
Pre-tax margin decline while TRAW shows 11.84% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
5.62%
Net income growth 50-75% of TRAW's 10.27%. Martin Whitman would scrutinize operations.
-120.69%
Net margin decline while TRAW shows 11.84% growth. Joel Greenblatt would examine position.
13.79%
Similar EPS growth to TRAW's 15.62%. Walter Schloss would investigate industry trends.
13.79%
Similar diluted EPS growth to TRAW's 15.62%. Walter Schloss would investigate industry trends.
10.10%
Share count reduction below 50% of TRAW's 7.97%. Michael Burry would check for concerns.
10.10%
Diluted share reduction below 50% of TRAW's 7.97%. Michael Burry would check for concerns.